欧洲杯买输赢规则百度百科

Cooperation

Top Core R&D
Liaoning xinyiyuanjin New Material Co., Ltd is Committed to the research and development and production of Ni-class anti-tumor drugs, Penan anti-inflammatory drugs, and tartin lipid-reducing drug intermediates, it has already independently developed more than 20 invention patents, focusing on the research and development of advanced pharmaceutical raw materials and intermediates. Manufacturing, In particular, it has the most advanced technology and manufacturing advantages in the field of anti-tumor, diabetes, and cardio-cerebrovascular intermediates.

 

Advantages in high-tech industrial fields
Liaoning xinyiyuanjin New Material Co., Ltd now has a R&D center, a standardized experimental center, a small type of GMP trial conversion workshop and an enterprise base; Provide various technical services such as impurity tracking, stability analysis and CTD document editing; It is equipped with 50 100L-5000 L reaction kettles with an annual manufacturing capacity of 300 tons; The high and low temperature reaction of -100 °C ~ 240 °C can be achieved, and it has the leading technical ability in the synthesis of heterocyclic compounds; To provide global pharmaceutical, agrochemical and electronic materials companies with innovative processes, technologies and competitive costs for customized synthesis and contract manufacturing of first-class services, solutions and products; The research and development team has professional chemical science knowledge; The technical director has served as a drug chemist for many years in research institutes and pharmaceutical companies; ISO certification began in 2016.

 

Working Together for Development
Liaoning xinyiyuanjin New Material Co., Ltd Seek long-term strategic partners, we in contract manufacturing, customized synthesis and project management, process research and development, analysis and transparent communication. We sincerely welcome domestic and foreign enterprises to join hands with us to seek common development and common growth.